ClinicalTrials.gg
Not yet recruitingNCT06587087Updated Sep 19, 2024

A Proof of Concept (PoC), Randomized, Controlled Study to Validate the Algorithm and Evaluate the Accuracy, Safety and Pain Level of the Smartest-AE in Comparison to Self-measure Blood Glucose Levels

An interventional study of Smartest-AE: The lancet that will be used will be the Vitrex Soft Lite lll 28G. in Diabetes Mellitus, Gestational Diabetes Mellitus (GDM) and Pre Diabetes, sponsored by Smartest Technologies. Not yet recruiting at 1 site in Israel. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-19.

Primary conditionDiabetes, GestationalRegistry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes, Gestational
Why
  1. The study's listed conditions name Diabetes, Gestational, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Smartest Technologies · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 9 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Diabetes, Gestational with a site in Israel — 6 open to participants now, 6 under way, none of them phase 3. Diabetes, Gestational · Israel.

Planned enrollment
4th of 15
300 · median 142
Started
2024
with 1 other
No phase
13 of 25
5 open now
Registered
24th of 25
by date

Among the 25 studies in Diabetes, Gestational with a site in Israel, this one is the 4th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2024, is one of 13 with no phase, and was the 24th registered.

Diabetes, Gestational

878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.

Browse Diabetes, Gestational studies →

Open to participants now

6 of the 25 studies in Diabetes, Gestational with a site in Israel are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Diabetes, Gestational with a site in Israel, or all of them as a file.
02

Study summary

The study is conducted in Israel so plain language for the study is exist in Hebrew only

Read the detailed description

Protocol Title:

A Proof of Concept (PoC), Randomized, Controlled study to validate the algorithm and evaluate the accuracy, safety and pain level of the Smartest-AE in comparison to self-measure Blood Glucose Levels

Investigational Device:

The Smartest-AE

Device Description:

The Smartest's System is intended to measure blood glucose levels in home environment. The Smartest's System consists of a disposable single-use device and a mobile app.

At this study Smartest-AE ("Smartest-AE") will be tested.

Study Overview:

The subjects will be enrolled from the Diabetes Mellitus (DM) clinics in the hospitals, endocrinological clinic, Internal divisions, obstetrics and gynecology department, diabetes in pregnancy and maternal and fetal medicine clinics.

Study subjects will be consecutively screened and enrolled into the study. The study will include up to 300 subjects, men and women aged 18 to 80.

The trial will encompass two distinct populations:

Group 1- Diabetes Mellitus Patients At least 100 subjects who diagnosed with Type I/Type II DM or GDM (Gestational Diabetes Mellitus), who regularly prick their fingers to monitor blood glucose levels and willing to participate in the study, and

Group 2- High risk individuals. at least 100 individuals who do not typically engage in finger pricking but are at high risk of developing prediabetes or diabetes due to to one of the following various risk factors:

  • BMI > 25
  • Age 45 or older
  • Have a parent or sibling with type 2 diabetes
  • Have ever had gestational diabetes
  • Hypercholesterolemia - according to blood level and\or using medication for lowering cholesterol
  • Dyslipidemia - according to blood level and\or using medication for lowering lipids Or any other risk factor according to the staff's discretion.

The study will be conducted in 2 stages:

Stage I- Algorithm verification- Blood glucose levels will be taken from the first 30 subjects in order to verify the algorithm. At the end of the enrollment of the first 30 cases an analysis will be done by Smartest's R\&D. If the algorithm yields correlation of R2>0.9, based on the calibration curves, the study will proceed to the second phase. In case the calibration does not show the expected R2 the Smartest's R\&D will re-assess the algorithm. If correction/ modification to the algorithm will be implemented another 30 subjects will be enrolled to verify the updated algorithm.

If the analysis following algorithm update, yields satisfying results (R2>0.9), the study will proceed to the second stage and the results of the 30 subjects used for verification will be included in the final analysis. If not, the study will be temporarily paused and the device algorithm will be re-assessed by Smartest's R\&D for accuracy and precision. Following that, another 30 subjects will be enrolled for algorithm verification. If the expected R2 is not obtained the study will be terminated.

Blood glucose levels will be measured for all 30/60/90 subjects using 2 devices:

  1. The Smartest-AE blood sample analyzer and
  2. A commercial standard reference approved glucometer including approved needles and strips.

The lancet that will be used for all subjects will be the Vitrex Soft Lite lll 28G.

All Subjects will complete a Numeric Rating Scale (NRS) questionnaire (Appendix A) to determine their level of pain from each device. NRS will be completed following each finger's pricking

Following NRS completion, blood will be taken from the subject's veins for blood glucose level that will be measured by the site's local lab.

NRS will not be completed following blood taken from the vein.

Stage II- Following algorithm verification and Smartest's approval to continue to stage II at least 200 subjects will be recruited.

Blood Glucose levels will be taken from each subject using the 2 devices; the Smartest-AE and the commercial glucometer.

The blood levels' results of the Smartest-AE will be compared to the commercial approved glucometer in order to assess accuracy. Subjects' comfort/pain level will be assessed following each finger's pricking using the Numeric Rating Scale (NRS) questionnaire

All Subjects will complete the NRS questionnaire to determine their level of pain from each device.

Following NRS completion, blood will be taken from the subject's veins for blood glucose level that will be measured by the site's local lab.

NRS will not be completed following blood taken from the vein. No follow-up period is expected.

Fingers III (middle) and IV (ring) of the non-dominant hand, will be pricked. Randomization will be used to allocate subjects that will be first tested with the Smartest-AE device and subjects that will be first tested with the commercial device. Finger III will always be the first to be pricked.

It was decided that subject IDs' even numbers will have the first prick with the Smartest-AE and subject IDs' odd numbers will have the first prick with the commercial device at each of the groups (1 and 2).

In case the device shows 'error 'or the results seems objectively, to be unreasonable (for eg: extremely high or low blood glucose level result that does not reflect subject physical condition at the time of test), another attempt will be done to achieve the blood glucose level. If the error will be obtained in the first test, then NRS will be completed by the subject subsequently to the test and the second attempt will be done only after the second (reference device) test will be performed. Up to 2 attempts are allowed for each system. Subject that has measurement results only from one system will be excluded from the analysis.

In case failings will be occurred in the venous blood test (either during the blood taking (problematic veins, etc.) or error received from the lab (hemolytic blood, etc.)), a second attempt will not be done and the result will be indicated as missing.

Study Population:

Adults volunteers, men and women, at least 25% of each gender at each group, at the ages of 18- 80 years old, diagnosed with Type I/Type II DM or GDM (Gestational diabetes Mellitus), who regularly prick their fingers to monitor blood glucose levels (Group 1, Diabetes Mellitus patients) and High risk individuals who do not typically engage in finger pricking but are at high risk of developing prediabetes or diabetes due to various risk factors (Group 2).

Hospital personnel are allowed to participate in this study as long they are not subjected directly to the principal investigator.

All subjects will confirm their willingness to participate in the study by signing an Informed Consent Form (ICF).

Study Objective:

To validate the algorithm and to evaluate the accuracy, safety and pain level of the Smartest-AE

Inclusion Criteria:

  1. Man or Woman, 18 through 80 years of age
  2. Diagnosed with either:

    • Group 1: Type I/II Diabetes Melitus/ GDM who regularly prick his/her fingers to monitor blood glucose levels or,
    • Group 2: High risk individuals who do not typically engage in finger pricking but are at high risk of developing prediabetes or diabetes due to one of the following various risk factors:

      • BMI > 25
      • Age 45 or older
      • Have a parent or sibling with type 2 diabetes
      • Have ever had gestational diabetes
      • Hypercholesterolemia - according to blood level and\or using medication for lowering cholesterol
      • Dyslipidemia- according to blood level and\or using medication for lowering lipids
      • Or any other risk factor according to the staff's discretion
  3. Able to self-test using a glucose level device
  4. Subject is willing and able to comply with protocol requirements and has provided a signed informed consent form (ICF)

Exclusion Criteria:

  1. Subject suffers from neuropathy, chronic pains, pain diseases, impaired sensation in the fingers\' area
  2. Subject diagnosed with dementia
  3. Subject diagnosed with major psychiatric disorders
  4. Subject use Narcotics or Analgesics, chronically or at the time of enrollment to the study and up to 4 hours prior to first test of the study
  5. Any other medical condition that is considered not eligible by the medical team members
  6. Subject Is not capable to report pain levels, objectively
  7. Participation in an interventional study at the time of enrollment to this study.

Study Duration :

One year depending on rate of subject recruitment. Duration for each participant: A single visit for couple of hours in the clinic or at the department during hospitalization.

Primary Endpoints:

Stage I- Smartest-AE system algorithm verification (R2>0.9) Stage II- Assess the accuracy of the Smartest-AE glucose measurements' results in comparison to the results received from a commercial approved glucometer.

Secondary Efficacy Endpoints:

  1. Subjects' pain level of the Smartest-AE vs. the commercial lancet using the NRS questionnaire
  2. Assess the accuracy of the Smartest-AE glucose measurements' results and the commercial glucometer results in comparison to the blood glucose level results of the venous blood test received from the local site's lab

Safety Endpoint:

Any adverse events reported throughout the study following finger pricking will be recorded, including severity (Adverse events such as: infection, exceptional bleeding, blisters, etc.)

Sample size:

The sample size was calculated based on the expected correlation between the commercial glucometer and the Smartest-AE using the G*Power software (version 3.1.9.6), focusing on the Pearson correlation coefficient. The following parameters were used:

Test Type: Exact, Correlation: Bivariate normal model. Tail(s): Two-tailed test. Effect Size (ρ H1): A correlation coefficient of 0.3, reflecting a realistic expectation of the correlation between the variables.

α Error Probability: The alpha level was set at 0.05, maintaining the standard criterion for statistical significance, where there is a 5% chance of a Type I error.

Power (1-β Error Probability): The power was set at 80% (0.8), indicating that there is an 80% probability of correctly rejecting the null hypothesis when it is false.

Correlation ρ H0: The null hypothesis correlation was set to 0, assuming no correlation between the variables.

The calculation results yielded a total sample size of 84 samples.

Smartest company received a grant from the Israel Innovation Authority (IIA). As part of the grant the IIA set a milestone of conducting a clinical trial in 200 subjects for this study purposes. Therefore, the study population size is higher than the necessary sample size.

Statistical Analysis:

Descriptive Statistics: Data will be described by group using mean, standard deviations, median, minimum, and maximum for continuous variables, and counts and proportions for categorical variables.

Subgroup Analysis Stratification by Experience: Differences in reported pain levels between experienced (Group 1) and naïve (Group 2) subjects will be tested using a regression analysis.

Gender Analysis: Differences in reported pain levels will be tested across gender, ensuring at least 25% representation from each gender in both groups.

Software and Data Management Software: All statistical analyses will be conducted using R software. R packages such as "ggplot2" for data visualization and "dplyr" for data manipulation will be utilized to handle and analyze the study data.

Data Management: Data will be coded and stored securely with access restricted to authorized personnel only.

Tables and Figures Table 1: Demographic and Baseline Characteristics by Group. Table 2: Summary Statistics of Blood Glucose Measurements from Smartest-AE, Commercial Glucometer, and Blood Tests.

Table 3: Subgroup Analysis of Pain Levels. Figure 1: correlation plot of Blood Glucose Measurements from Smartest-AE, Commercial Glucometer, and Blood Tests.

Figure 2: Raincloud plots of Pain Levels Reported on NRS by gender.

Handling of Missing Data Missing Data Policy: Subjects missing measurements from either the Smartest-AE or the commercial glucometer will be excluded from the analysis.

Data Imputation: No imputation will be performed for missing glucose measurements; only complete case analysis will be used.

03

Conditions studied

  • Diabetes Mellitus
  • Gestational Diabetes Mellitus (GDM)
  • Pre Diabetes

Browse trials for

Keywords

  • Diabetes
  • Gestational Diabetes Mellitus (GDM)
  • Pre-Diabetes
04

In context

Diabetes, Gestational Reclassified

878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.

This study's planned enrollment of 300 is above the median of 110 across 563 interventional studies indexed under Diabetes, Gestational.

Browse Diabetes, Gestational studies →

Lead sponsor

This is the only study on the registry with Smartest Technologies as lead sponsor.

Compared within Diabetes, Gestational, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Man or Woman, 18 through 80 years of age
  2. Diagnosed with either:

    • Group 1: Type I/II Diabetes Melitus/ GDM who regularly prick his/her fingers to monitor blood glucose levels or,
    • Group 2: High risk individuals who do not typically engage in finger pricking but are at high risk of developing prediabetes or diabetes due to one of the following various risk factors:

      • > 25
      • Age 45 or older
      • Have a parent or sibling with type 2 diabetes
      • Have ever had gestational diabetes
      • Hypercholesterolemia - according to blood level and\or using medication for lowering cholesterol
      • Dyslipidemia- according to blood level and\or using medication for lowering lipids
      • Or any other risk factor according to the staff's discretion
  3. Able to self-test using a glucose level device
  4. Subject is willing and able to comply with protocol requirements and has provided a signed form (ICF)

Exclusion criteria

Exclusion Criteria:

    1. Subject suffers from neuropathy, chronic pains, pain diseases, impaired sensation in the fingers\' area 2. Subject diagnosed with dementia 3. Subject diagnosed with major psychiatric disorders 4. Subject use Narcotics or Analgesics, chronically or at the time of enrollment to the study and up to 4 hours prior to first test of the study 5. Any other medical condition that is considered not eligible by the medical team members 6. Subject Is not capable to report pain levels, objectively 7. Participation in an interventional study at the time of enrollment to this study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Investigational Glucose level device- Smartest-AE

    The Smartest's System is intended to measure blood glucose levels in home environment. The Smartest's System consists of a disposable single-use device and a mobile app.

    Device: Smartest-AE: The lancet that will be used will be the Vitrex Soft Lite lll 28G.

  • Active comparator
    Commercial Glucometer

    Device: Smartest-AE: The lancet that will be used will be the Vitrex Soft Lite lll 28G.

Interventions

  • DeviceSmartest-AE: The lancet that will be used will be the Vitrex Soft Lite lll 28G.

    The lancet that will be used for all subjects will be the Vitrex Soft Lite lll 28G.

07

What researchers measure

Primary outcomes

  1. Algorithm verification

    Stage I- Smartest-AE system algorithm verification (R2\>0.9)

    Time frame: 1 months

  2. Stage II- Accuracy

    Stage II- Assess the accuracy of the Smartest-AE glucose measurements' results in comparison to the results received from a commercial approved glucometer.

    Time frame: 3 months

Secondary outcomes

  1. Pain Level

    Subjects' pain level of the Smartest-AE vs. the commercial lancet using the NRS questionnaire

    Time frame: 4 months

  2. accuracy vs. lab results

    Assess the accuracy of the Smartest-AE glucose measurements' results and the commercial glucometer results in comparison to the blood glucose level results of the venous blood test received from the local site's lab

    Time frame: 4 months

Other outcomes

  1. Safety

    Any adverse events reported throughout the study following finger pricking will be recorded, including severity (Adverse events such as: infection, exceptional bleeding, blisters, etc.)

    Time frame: 4 months

08

Study locations

1 site
  • The BARUCH PADEH Medical Center, Poriya
    Poriya, the Lower Galilee 15208, Israel
    • Enav Yefet, MD · Contactenyefet@tzmc.gov.il · 972-52-386-2160
    • Keren Lubenfeld, Stduy coordinator · Contactkelubenfel@tzmc.gov.il · 972-50-5709562
    • Enav Yefet, MD · Contact
    • Muhamad Badrarna, MD · Contact
    • Sofia Soltzman, MD · Contact
    • Keren Lubenfeld · Contact
    • Lilach Yaacov-Shavit · Contact
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2024; primary completion for Jan 2025, 4 months later.

Of 309 interventional studies with no phase under Diabetes, Gestational, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 48. This study's planned 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2024
First posted
Sep 19, 2024
StartEst.
Sep 20, 2024
Primary completionEst.
Jan 31, 2025
CompletionEst.
Feb 15, 2025
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06587087
Lead sponsor
Smartest Technologies
Collaborators
Israel Innovation Authority
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Sep 20, 2024 (estimated)
Primary completion
Jan 31, 2025 (estimated)
Completion
Feb 15, 2025 (estimated)
Last update
Sep 19, 2024

Study contacts

Ariel Horwitz, CEO
Contact
ariel@smarttest.io
972-54-8884330
Eliezer Anavi, CTO
Contact
eliezer@smarttest.io
972-54-3970629
Enav Yefet, MD
principal investigator · Baruch Padeh Medical center Poriya

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion